We leverage our proprietary technology platform to design and deliver safe and effective therapies for neurological disorders.
According to the World Health Organisation (WHO), neurological disorders are one of the greatest threats to public health globally. Over the last couple of decades several strategies have failed to offer safe and effective therapeutic avenues to patients. At SMDG, we leverage our novel platform technology and library of new class of nanoparticles combined with the next generation nucleic acid therapies designed within our discovery programmes to deliver life saving therapies.
Our primary focus and an expanding portfolio of R & D programmes
Alzheimer's disease (AD) is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease—those with the late-onset type—symptoms first appear in their mid-60s.
Parkinson's disease (PD) is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Parkinson's symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty walking and talking.
Rare Neurological Disorders
SMDG is highly committed to leverage its novel new class of nanoparticles and its proprietary platform technology to design and deliver safe and effective therapies for rare neurological disorders.
"A disease is defined as rare if it has a prevalence of less than 5 per 10 000. However, collectively, rare diseases are surprisingly common, creating a huge health-care and economic burden. There are an estimated 5000–8000 rare diseases, and about 5–8% of the European population is thought to be affected by a rare disease, many of which have neurological manifestations. In the U.S.A, it's estimated that over 25-30 million people live with rare diseases. About 80% of rare diseases have a genetic basis, and onset is often in childhood." The Lancet Neurology